𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

✍ Scribed by Matrana, M.R.; Duran, C.; Shetty, A.; Xiao, L.; Atkinson, B.J.; Corn, P.; Pagliaro, L.C.; Millikan, R.E.; Charnsangave, C.; Jonasch, E.; Tannir, N.M.

Book ID
122792236
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
454 KB
Volume
49
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Clinical factors associated with outcome
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
✍ Toni K. Choueiri; Jorge A. Garcia; Paul Elson; Mohamad Khasawneh; Saif Usman; Al πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Therapy targeted against the vascular endothelial growth factor (VEGF) pathway is a standard of care for patients with metastatic renal cell carcinoma (RCC). The identification of patients who are more likely to benefit from these agents is warranted. ## METHODS. In to